title: Multiple sclerosis: Switching sides--fingolimod versus injectable MS therapies.
authors.affiliation: Mellen Center for MS Treatment and Research, Neurological institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA.
authors.forename: Ian T
authors.initials: IT
authors.lastname: Rossman
authors.affiliation: Mellen Center for MS Treatment and Research, Neurological institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA.
authors.forename: Jeffrey A
authors.initials: JA
authors.lastname: Cohen
mesh_terms: D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016899:Interferon-beta / Q000627:therapeutic use*; D008297:Male; D009103:Multiple Sclerosis / Q000188:drug therapy*; D011409:Propylene Glycols / Q000627:therapeutic use*; D013110:Sphingosine / Q000031:analogs & derivatives*
chemical_list: D007155:Immunologic Factors; D007166:Immunosuppressive Agents; D011409:Propylene Glycols; D016899:Interferon-beta; D013110:Sphingosine